Allergy

Asthma control or severity: that is the question
pp. 95-101(7)
Authors: Humbert, M.; Holgate, S.; Boulet, L.-P.; Bousquet, J.

GINA guidelines on asthma and beyond
pp. 102-112(11)
Authors: Bousquet, J.; Clark, T. J. H.; Hurd, S.; Khaltaev, N.; Lenfant, C.; O'Byrne, P.; Sheffer, A.

Should asthma control be the guide for therapeutic decision-making?
pp. 113-115(3)
Author: Stempel, D. A.

Control and severity: complementary approaches to asthma management
pp. 116-119(4)
Authors: Roche, N.; Godard, P.

Quantification of asthma control: validation of the Asthma Control Scoring System
pp. 120-125(6)
Authors: LeBlanc, A.; Robichaud, P.; Lacasse, Y.; Boulet, L.-P.

Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma
pp. 126-133(8)
Authors: Sullivan, S. D.; Rasouliyan, L.; Russo, P. A.; Kamath, T.; Chipps, B. E.

The limitations of severe asthma: the results of a European survey
pp. 134-141(8)
Authors: Dockrell, M.; Partridge, M. R.; Valovirta, E.

Asthma score: predictive ability and risk factors
pp. 142-148(7)
Authors: Sunyer, J.; Pekkanen, J.; Garcia-Esteban, R.; Svanes, C.; Künzli, N.; Janson, C.; de Marco, R.; Antó, J. M.; Burney, P.

Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma
pp. 149-153(5)
Authors: Brown, R.; Turk, F.; Dale, P.; Bousquet, J.

Omalizumab decreases nonspecific airway hyperresponsiveness in vitro
pp. 154-161(8)
Authors: Berger, P.; Scotto-Gomez, E.; Molimard, M.; Marthan, R.; Le Gros, V.; Tunon-de-Lara, J. M.

T-cell activation in occupational asthma and rhinitis
pp. 162-169(8)
Authors: Mamessier, E.; Milhe, F.; Guillot, C.; Birnbaum, J.; Dupuy, P.; Lorec, A.-M.; Vervloet, D.; Magnan, A.

Chemokine receptor expression on allergen-specific T cells in asthma and allergic bronchopulmonary aspergillosis
pp. 170-177(8)
Authors: Garcia, G.; Humbert, M.; Capel, F.; Rimaniol, A. C.; Escourrou, P.; Emilie, D.; Godot, V.

Inverse relation between nasal fluid Clara Cell Protein 16 levels and symptoms and signs of rhinitis in allergen-challenged patients with intermittent allergic rhinitis
pp. 178-183(6)
Authors: Benson, M.; Fransson, M.; Martinsson, T.; Naluai, Å. T.; Uddman, R.; Cardell, L. O.

Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis
pp. 184-189(6)
Authors: Bieber, T.; Vick, K.; Fölster-Holst, R.; Belloni-Fortina, A.; Städtler, G.; Worm, M.; Arcangeli, F.

Amoxicillin conjugates to HLA class I molecules and interferes with signalling through the ILT2/LIR-1/CD85j inhibitory receptor
pp. 190-196(7)
Authors: Morel, E.; Bellón, T.

Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines
pp. 197-206(10)
Authors: Crameri, R.; Flückiger, S.; Daigle, I.; Kündig, T.; Rhyner, C.

Correlation among FEV₁, nitric oxide and asthma control test in newly diagnosed asthma
pp. 207-208(2)
Authors: Senna, G.; Passalacqua, G.; Schiappoli, M.; Lombardi, C.; Wilcock, L.

Association between a genetic variation of CC chemokine receptor-2 and atopic asthma
pp. 208-209(2)
Authors: Kim, Y.-K.; Oh, H.-B.; Lee, E.-Y.; Gho, Y. S.; Lee, J.-E.; Kim, Y.-Y.

Anaphylaxis to kangaroo meat - identification of a new marsupial allergen
pp. 209-211(3)
Authors: Boyle, R. J.; Russo, V. C.; Andaloro, E.; Mehr, S. M.; Tang, M. L.-K.

Occupational asthma due to spores of Pleurotus ostreatus
pp. 211-212(2)
Authors: Vereda, A.; Quirce, S.; Fernández-Nieto, M.; Bartolomé, B.; Sastre, J.